Canadian clinical-stage biotechnology company Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) announced on Tuesday that it has begun patient enrolment at Tel Aviv Sourasky Medical Center for its FDA-approved Phase I/IIa trial of CMND-100 in Alcohol Use Disorder.

The activation of the Israeli site, led by Principal Investigator Prof. David Zeltser, adds to a network that includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center.

The study is assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a proprietary non-hallucinogenic oral MEAI-based compound.

Clearmind reported that top-line findings from the first completed cohort showed favourable safety and adherence with no serious adverse events.

The company, which develops psychedelic-derived therapeutics for under-treated conditions, holds a portfolio of nineteen patent families and 31 granted patents as it advances its therapeutic pipeline.